Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Obat: Jurnal Riset Ilmu Farmasi dan Kesehatan
Eman Hamza Mohammed
Unknown Affiliation
Health Professions Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Molecular Identification of Pseudomonas Aeruginosa Isolated from Operations Hall and Their Antibiotics Resistance Eman Hamza Mohammed
OBAT: Jurnal Riset Ilmu Farmasi dan Kesehatan Vol. 2 No. 2 (2024): March : OBAT: Jurnal Riset Ilmu Farmasi dan Kesehatan
Publisher : Asosiasi Riset Ilmu Kesehatan Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61132/obat.v2i4.585

Abstract

This study aimed to determine the P.aeruginosa that causes infectionby molecular technique. Bacterial isolated and identificatedphenotypically and genotypically, and their antibiogram detection. Onehundred clinical specimens were collected from patients suffering fromdifferent clinical infections during the period from September 2024 toJanuary 2024 in AL-Sadder Medical city. The identification of theP.aeruginosa isolates depended on colonial morphology, microscopicexamination and biochemical tests. P.aeruginosa had the ability toproduce capsule, biofilm , adhesion, protease, bacteriocin, haemolysin,B-lactamase and gelatinase. Regard to molecular study 16 RNA geneappeared th at all isolates due to (100%) of P. aeruginosa isolatesTo conclusion that P. aeruginosa able to produce sever pathogenicitymarkers which responsible for pathogenicity of P.aeruginosa infections.
Review Of "Chasing Resistance: New Antibiotics For A Changing Landscape Eman Hamza Mohammed
OBAT: Jurnal Riset Ilmu Farmasi dan Kesehatan Vol. 2 No. 4 (2024): Juli : OBAT: Jurnal Riset Ilmu Farmasi dan Kesehatan
Publisher : Asosiasi Riset Ilmu Kesehatan Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61132/obat.v2i4.989

Abstract

Antimicrobial resistance (AMR) is an age-old biological phenomenon, as evidenced by its evolutionary history and abundance of environmental immunity Antibiotics used by humans contributes to resistance to acquired disease, a public health issue that drives the selection of resistance genes. A.M.R. One of the most important strategies to combat AMR is the search for new antibiotics. During the 1980s, existing products were either enhanced or modified in antibiotics currently on the market. The World Health Organization (WHO) warns of limited new candidates and highly characterizes the current pipeline. After careful analysis of preclinical and therapeutic pipelines, it seems expected that very few new antibiotics will enter the market in the coming years . Most of these candidates do not meet the new standards required to adequately address the growing threat of antimicrobial resistance (AMR).The key principles to cope with the rapidly emerging AMR are diversity and innovation which are done. R&D efforts should address new antibiotic resistance. Although there is promising potential to change the dynamics between the spread of AMR, antibiotic reserves, and meeting new lead standards, we examine the historical context and challenges associated with drug a kills bacteria detection, and various other processes. Let us describe the proposed methods of revitalizing the pipeline.
Co-Authors